NICE 'cash-back' deal unlikely to be the norm

The NHS 'cash-back' scheme for bortexomib (Velcade) approved by NICE last week is unlikely to become the norm, say experts.

For the first time, NICE approved NHS use of a drug under a response-rebate scheme. This means that if a patient shows no response to the drug, the manufacturer has to refund its cost to the NHS.

NICE said the scheme was only considered after being suggested by manufacturer Janssen-Cilag.

If response-rebate is to be considered in the future, it would have to be suggested by manufacturers and be approved in principle by the DoH.

A NICE spokesman said: 'There are a number of factors that might need to be considered, such as whether it would be clinically appropriate for continuation of treatment to be determined on the basis of an appropriate response measure and how well the response measure predicts actual health outcomes.'

The scheme applies to patients with multiple myeloma who have had one prior therapy and for whom blood marrow transplantation has failed or is unsuitable.

At first relapse, eligible patients can be given bortexomib. If they show a full or partial response they will be allowed to continue with the treatment, funded by the NHS.

If the patient fails to respond, treatment will stop and Janssen-Cilag will refund the NHS the cost of the drug, says NICE.

Richard Ley, spokesman for the Association of the British Pharmaceutical Industry, said the scheme was likely to be 'the exception, not the norm'.

'They can't all do it,' he said. 'The reason is that Velcade is in a peculiar position.'

Within a few weeks of use, doctors can identify markers to see if the drug is being effective.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Sign pointing to hospital

NHS England seeks to clarify GPs' responsibilities when using advice and guidance

New guidance from NHS England has set out the clinical responsibilities and medicolegal...

Widespread joint pain - red flag symptoms

Presentations and red flag symptoms that may alert you to potentially serious conditions...

Talking General Practice logo

Podcast: Supporting neurodivergent doctors and staff in general practice

Talking General Practice speaks to GPs Dr Beckie Akroyd and Dr Catherine Bell about...

BMA Scotland GP committee chair Dr Andrew Buist

General practice in Scotland 'in serious trouble', warns BMA Scotland GP chair

General practice in Scotland has reached a tipping point, with demand far outstripping...

Hospital entrance

NHS England issues warning over norovirus and rising winter pressures

Almost three times as many people were in hospital with norovirus last week compared...

BMA Northern Ireland GP committee chair Dr Alan Stout

Northern Ireland GPs face deepest-ever crisis as practices hand back contracts

Northern Ireland's GP leader has warned that general practice in the region is facing...